摘要
目的分析原发性肝癌介入治疗患者联合应用沙利度胺对其VEGF、bFGF以及T细胞水平的影响。方法选取100例兰州大学第一医院2017年1月—2019年1月期间收治的原发性肝癌患者,随机分为两组,均给予介入手术治疗,研究组治疗7 d后口服沙利度胺治疗,对照组口服安慰剂治疗,比较两组治疗效果。结果研究组治疗后VEGF水平为(240.3±6.8)pg/ml,bFGF为(71.1±8.9)mg/L,与对照组的(315.6±8.4)pg/ml和(92.3±10.4)mg/L比较,差异有统计学意义(P<0.05)。研究组治疗后的RBC-C3bRR、DTER水平高于对照组,RBC-ICR水平低于对照组,组间差异有统计学意义(P<0.05)。研究组治疗后CD3+为(71.8±6.9)%,CD4+为(40.7±5.3)%,显著高于对照组的(41.7±5.5)%和(33.2±4.5)%,组间差异有统计学意义(P<0.05)。研究组与对照组治疗后的CD4+/CD8+分别为(1.79±0.54)和(1.24±0.38),差异有统计学意义(P<0.05)。结论原发性肝癌患者在介入治疗基础上,联合应用沙利度胺治疗,可有效改善患者的VEGF、b FGF水平和免疫功能,调节T细胞水平,可加强应用。
Objective To analyze the effects of thalidomide combined with interventional therapy on the levels of vascular endothelial growth factor,bFGF and T cells in patients with primary hepatocellular carcinoma.Methods 100 patients with primary hepatocellular carcinoma admitted to the hospital from January 2017 to January 2019 were randomly divided into two groups.They were treated with interventional surgery.The study group was treated with thalidomide orally 7 days later,and the control group was treated with placebo orally.The therapeutic effects of the two groups were compared.Results After treatment,the levels of vascular endothelial growth factor(VEGF)and bFGF in the study group were(240.3±6.8)pg/ml and(71.1±8.9)mg/L,respectively.There were significant differences between the study group and the control group(315.6±8.4)pg/ml and(92.3±10.4)mg/L(P<0.05).After treatment,RBC-C3bRR and DTER levels in the study group were higher than those in the control group,and RBC-ICR levels were lower than those in the control group,with significant differences between the two groups(P<0.05).After treatment,CD3+and CD4+in the study group were(71.8±6.9)%and(40.7±5.3)%,which were significantly higher than those in the control group(41.7±5.5)%and(33.2±4.5)%.There was a significant difference between the two groups(P<0.05).The CD4+/CD8+of the study group and the control group after treatment were(1.79±0.54)and(1.24±0.38),respectively,with significant difference(P<0.05).Conclusion Combined thalidomide therapy on the basis of interventional therapy can effectively improve the levels of vascular endothelial growth factor,bFGF and immune function,regulate the level of T cells,and strengthen the application of thalidomide in patients with primary hepatocellular carcinoma.
作者
郭铮
铁镔
李立
刘荣
方晋
GUO Zheng;TIE Bin;LI Li;LIU Rong;FANG Jin(Department of Interventional Medicine,First Hospital of Lanzhou University,Lanzhou 73000,China)
出处
《中国全科医学》
CAS
北大核心
2020年第S02期112-114,共3页
Chinese General Practice
关键词
介入治疗
原发性肝癌
沙利度胺
T细胞水平
免疫功能
Interventional therapy
Primary liver cancer
Thalidomide
T cell level
Immune function
